The South African Health Products Regulatory Authority (SAHPRA) has terminated the “Ivermectin Controlled Compassionate Use Access Programme” that allowed the use of the drug to treat Covid-19.
“Given that there is currently no credible evidence to support a therapeutic role for Ivermectin in Covid-19, SAHPRA has decided to terminate the Programme with immediate effect,” said the health products regulator on Monday.
“No further importation of unregistered Ivermectin products will be allowed, and health facilities will no longer be enabled to hold bulk stock in anticipation of prescriptions for such unregistered Ivermectin products.
“Prescribers will still be expected to report on the clinical outcomes achieved in patients for whom Section 21 approval has been issued.
Ivermectin is an antiparasitic drug. After its discovery in 1975, its first uses were in veterinary medicine to prevent and treat heartworm and acariasis
The use of Ivermectin for the treatment and prevention of Covid-19 received a lot of public interest in 2020.
Despite early evidence, mostly from studies with a small number of patients and conducted with varying degrees of scientific rigour, indicating some potential benefit in the management of Covid-19, SAHPRA said it had reviewed its stance on the drug.
At the time, there were reports of illicit Ivermectin-containing products entering the South African market, as well as the use of veterinary Ivermectin products.
In response to the demand for access to Ivermectin for human use, SAHPRA, in January this year, enabled a controlled compassionate use programme (“the Programme”), relying on section 21 of the Medicines and Related Substances Act.
However, on Monday SAHPRA said: “studies that suggested potential efficacy of Ivermectin in the prevention and treatment of Covid-19 and which motivated the adoption of the Programme have since been retracted.
SAHPRA added: “The FDA has not authorized or approved Ivermectin for the treatment or prevention of Covid-19 in people or animals. Ivermectin has not been shown to be safe or effective for these indications”.
“The findings of two large clinical trials conducted in 2021 do not support the use of Ivermectin for patients with Covid-19.
“Two national health organisations updated their guidelines and do not recommend the use of Ivermectin in patients with Covid-19, except in the context of clinical trials.”
As a result of these considerations, the SA regulator said it was ending its “Ivermectin Controlled Compassionate Use Access Programme”.
The Programme was initiated in January 2021. Permission was granted to five importers of unregistered Ivermectin oral solid dosage forms, and health facilities were enabled to hold bulk stock, in anticipation of patient needs.
Individual named patient applications were still required after prescribers had initiated the use of Ivermectin.
SAHPRA said it also undertook to monitor the emerging evidence of safety and efficacy, for both treatment and prevention.
Although the regulator warned that users could also overdose on Ivermectin, which can cause nausea, vomiting, diarrhea, hypotension (low blood pressure), allergic reactions (itching and hives), dizziness, ataxia (problems with balance), seizures, coma and even death, callers to radio stations were not convinced.
Some claimed the drug had helped them recover from Covid-19 within three days of being in ICU.
Others disputed the findings of the research and insisted it was effective as a Covid-19 treatment and pointed to anecdotes of people who used the drug and recovered.


